eligibility_summary
Eligible: untreated follicular lymphoma grade 1–3a, stage II–IV, measurable disease, needs therapy (B symptoms, fatigue, splenomegaly, compression, lymphoma-related cytopenias, effusion, or ↑LDH/B2M), consent/compliance, acceptable performance status/organ function, negative pregnancy test if applicable. Exclude: CNS disease, transformation/grade 3b, other malignancy, severe mAb allergy, major surgery <14 days, pregnant/breastfeeding, or investigator deems unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Open-label, single-arm phase 2 trial testing a chemotherapy-free regimen of zanubrutinib (small-molecule BTK inhibitor), rituximab (anti-CD20 monoclonal antibody), and venetoclax (small-molecule BCL-2 inhibitor) in previously untreated follicular lymphoma. Mechanisms: zanubrutinib blocks BTK within the B-cell receptor signaling pathway to reduce malignant B-cell proliferation and survival, rituximab binds CD20 on B cells, inducing depletion via antibody-dependent cellular cytotoxicity, complement activation, and apoptosis, venetoclax inhibits anti-apoptotic BCL-2 to trigger mitochondrial apoptosis. Targets: CD20+ lymphoma B cells, BCR/BTK signaling, BCL-2–mediated survival. Design: cycles 1–3 zanubrutinib+rituximab, cycles 4–9 continue if complete response, otherwise add venetoclax (ramp to 400 mg daily).